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Many Species. One Medicine.™
about  the  cover : 
Dr. Dottie Brown examines Rocky, a participant in a clinical study. 
Right off the historic courtyard of the University of Pennsylvania School of Veterinary Medicine sits a large, sparsely decorated office, broken into a maze of cubicles. The nondescript nature of this space   belies the fact that for the past six years it has 
served as the nerve center for an array of small-animal clinical 
trials, stretching from this campus to the bench research facilities 
of biomedical partners near and far. 
Outside, a simple placard announces it as the Veterinary 
Clinical Investigation Center (VCIC). Inside, a blackboard 
mounted high on the back wall carries an inventory of some 
two dozen current trials. A cursory review of partner institutions 
past and present – the National Institutes of Health, Johns 
Hopkins University, Penn State Hershey, as well as nearby Penn 
Medicine and Children’s Hospital of Philadelphia – indicates  
two things: the caliber and aspirations of these activities are  
high, and most of the intended benefits serve both animal and 
human patients. 
Of the 28 veterinary schools in the United States, Penn Vet 
is the first to create a research facility dedicated to the immense 
promise of translational research. 
The Power of One
The words behind the Penn Vet mission – “Many Species, One 
Medicine”– represent an understanding that veterinary practice 
comprises diverse enterprises with a common purpose. 
Much more recently, biomedical leaders have latched on 
to the expression “one medicine” to describe the correlation 
between many human and animal diseases, especially those found 
in domesticated animals, primarily cats and dogs. A short list  
of related conditions includes numerous cancers, infectious 
diseases, allergies, autoimmune deficiencies, osteoarthritis and 
chronic pain.
Joan Hendricks, V’79, GR’80, the Center’s founding 
director and current Dean, was in many ways a perfect fit 
for such an innovative concept. A passionate researcher who 
specializes in the molecular basis of sleep regulation and 
function, she holds a secondary appointment from Penn’s School 
of Medicine and served as section chief for critical care at the 
Matthew J. Ryan Veterinary Hospital.
“The best investment we can make as a School and a 
community is to build our clinical research capabilities,” says 
Dean Hendricks. “It helps us recruit and retain the best faculty, 
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when dr. John lewis, v’97 went to the 2005 
groundbreaking ceremony for the vernon and shirley 
hill pavilion, he never expected that just being 
there would help him break new ground in treating 
patients with feline oral squamous cell carcinoma.
“it turned out a penn vet classmate is married to 
dr. tom o’brien, a lankenau researcher working on 
an experimental squamous cell drug,” says the assistant 
professor of dentistry and oral surgery. “one thing 
led to another and we began working together.”
with the support of the vCiC, the two men 
embarked on a fruitful collaboration. like many 
biomedical researchers, o’brien was looking for an 
intermediary step between mouse models and human 
clinical trials to provide important insights into his 
drug’s potential adverse effects. lewis sought better 
options for the usually advanced and often inoperable 
head and neck tumors he saw in his feline patients.
as with many joint projects, a creative combination 
of funding underwrites their collaboration, from 
governmental – the national institutes of health – to 
very personal – a penn vet donor, kathleen Jack, whose 
cat bud passed away from a squamous cell tumor.
across medicine, finding more efficient ways to identify 
promising drugs is a key goal. of all the drugs developed, 
only one in five make it from phase i human clinical trials to 
the market. using small-animal studies to identify downsides 
early on has major advantages: biomedical partners are able 
to use human resources more sparingly and funders and 
pharmaceutical companies can target financial resources 
to those studies that continue to produce results.
of course, not all human drug development can 
leverage the advantages of veterinary trials. those that 
can lewis likes to call “sparedels” – a new term he 
credits to his penn vet colleague dr. lillian duda, v’90, 
an adjunct associate professor of radiation oncology.
“it stands for ‘spontaneous parallel reciprocal models’ 
with human disease,” explains lewis. “i think this may soon 
be accepted shorthand as more and more researchers on 
the biomedical/human side of things realize translational 
medicine is the future of bench-to-bedside research. 
‘sparedels’ will always provide you with more information 
and more advances than experimental, induced cancers.”
in addition to the parallel advances he is 
achieving with o’brien, lewis counts himself 
fortunate to advance understanding about how 
his feline patients tolerate medications.
“the vCiC is allowing us, as clinician educators, 
to perform scholarly activity,” says lewis. “you’re 
usually pulled in four different directions at a time – 
educating fourth-year students, rotating through service, 
educating clients, teaching residents. research is like 
a quiet child – one who deserves more attention but 
doesn’t always get it. the vCiC has helped change 
this reality for good – and for the common good.”
commongood
owner George heath with 11-year-old rocky.  
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raise the stature and importance of research 
as it threads through Penn Vet’s work, and 
connects this institution and its patients to 
breakthrough diagnostics and therapeutics.”
A Delicate Balance
Without an integrated center such as VCIC 
to oversee and support these clinical trials, 
many of the activities underway would not 
take place.
“I first realized how difficult it is to find 
time for research when I began measuring 
and managing chronic pain in dogs,” 
says Dr. Dorothy Cimino Brown, the 
Center’s current director. “The research 
end of things always tends to suffer. That 
needed to change.”
Brown shared her perspective with 
Dean Hendricks, then Interim Chair of 
Clinical Studies, unaware that the latter was 
already in talks with Pfizer about building a 
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relationship with Penn Vet. The pharmaceutical giant embraced 
the novel concept and the nascent Center set up shop managing 
a small nucleus of Pfizer animal health studies. 
These first trials provided useful primers in navigating 
regulations and managing the logistical side of studies. “For 
a canine osteosarcoma study – where our clinic normally 
encounters just one or two cases a month – we had to find 100 
subjects. How do you do that?” Brown found herself asking. 
“We had to learn, practically overnight, how to creatively 
recruit participants.”
Connections to community vets, especially alumni, were 
tapped. Spots were aired on KYW News Radio. Over the 
course of the year, one by one, the 100 dogs came through  
the door.
Next followed the need for stronger human resources. The 
first hire was a nurse/clinical trial coordinator – there are four 
today – to gather robust data, keep protocols and support 
reporting. Brown herself went back to school, earning a Masters 
in Clinical Epidemiology from Penn to ensure greater in-house 
expertise about clinical trial design, implementation and analysis. 
The Center readily tapped into Penn Vet’s own technological 
resources, from the latest in magnetic resonance imaging 
to digital and intra-oral radiology, and found an essential 
on-campus partner in the Investigational Drug Service at 
the Hospital of the University of Pennsylvania. A “research-
only” pharmacy, it has the capacity to compound and dispense 
investigational drugs.
Continuum of Support
The Center staff, comprised entirely of veterinarians, nurses 
and vet technicians, quickly became expert at working with 
clients who enroll their companion animals for VCIC studies. 
At the heart of these relationships is a rigorous informed-consent 
process for each meticulously designed and peer-reviewed study.
“It’s so important to express the scope, risk and potential 
benefits accurately so owners and animals both feel protected,” 
says Brown. “You especially cannot mislead owners of terminal 
patients. They have to feel motivated to participate.”
One of VCIC’s current clients, George Heath, has embraced 
the opportunity to enroll Rocky, his beloved 11-year-old 
Rottweiler, in the osteosarcoma study.
“I found out about the study from my local veterinarian,” 
says Heath, who lives in Chester County, Pennsylvania — an 
hour-long drive from Ryan Veterinary Hospital in good traffic 
but a relatively short trip when measured against his companion’s 
welfare and happiness.
When Rocky arrived at Penn in March, a limp detected 
the previous September and first treated with a common anti-
inflammatory drug, had turned into a debilitated gait that 
indicated a great deal of pain. With radiation and chemotherapy 
the only other options, the VCIC study, which focuses on pain 
management, was a welcome alternative.
“To me, being part of this study means a lot because Rocky 
is family. I’ve had him since he was a puppy,” Heath explains. 
“This study offers better options and Rocky’s doing better. He’s 
happy and he’s comfortable. If it helps other dogs and even 
humans, so much the better.”
Each month, Heath and Rocky make the trip to the 
Penn Vet campus for a physical and a data “dump” from the 
microchip tag on Rocky’s collar, which constantly tracks his 
vital signs and behavior. 
Beyond these check-ups and information gathering, Heath 
appreciates VCIC’s human touch. In this case, Molly Love, 
CW’74, NU’81, GNU’84, is the nurse/clinical trial coordinator 
who oversees Rocky’s case. “Molly’s always there by telephone 
or e-mail if I need her,” he says. “She sends reports to my vet 
right away. I couldn’t ask for more. 
vCiC staff member, Molly love, Cw’74, nu’81, Gnu’84. 
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. . . well-regulated Diabetes Mellitus
. . . bone cancer in need of pain management
. . . diagnosed with splenic hemangiosarcoma
. . . mast cell tumors not amenable to surgery
. . .  Or a Doberman Pincher who needs a free cardiac evaluation
Penn’s Veterinary Clinical Investigation Center (VCIC) is looking for  
you and your dog. Please call us to find out more about clinical trials.  
Your dog may be qualified to participate in a study at the University  
of Pennsylvania, Matthew J. Ryan Veterinary Hospital. For more 
information call 215-573-0302 or email VCIC@vet.upenn.edu.  
Please check our website for information  
about other ongoing studies in the  
VCIC at www.PennVCIC.org 
Do you have  
 a dog with…
“In fact, I was just telling Molly my vet diagnosed another 
Rottweiler with osteosarcoma. If that patient needs a reference, I 
said, call me. I’ll let them know what a great program this is.”
Like Heath, many participants see VCIC as a welcome 
lifeline, offering up-to-date information, access to novel 
drugs and techniques, more affordable costs, and, above all, 
the knowledge that they are helping future generations of 
companion animals – and now people.
On September 23, 2009, the National Institutes of Health 
treated the first human patient in its Phase 1 study of the pain 
management treatment given to Rocky. The study, designed 
for people with end-stage cancer, is highly restricted in its 
participation criteria. Early results indicate that the patient  
was free of debilitating daily pain. Truly, one — translational  
— medicine.
Burgeoning Potential
From alternative medications to nanotechnology, VCIC never 
stops seeking new ways to expand what can be accomplished 
through translational research.
Today, the Center is made possible through gifts, grants and 
clinical trials. Funding for new trials and advancing the Center’s 
mission are being sought.
“The first two quarters of 2009 saw more studies initiated 
than in all of 2008,” says Brown. “As investigators work with 
us, they realize how much better it is to take advantage of our 
infrastructure. Owners are happier to know they are advancing 
science for the future. For us, it’s better all around.”
The Center’s team is happy, too, knowing that, among those 
cubicles, they are indeed making history.
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onlineupdate
to see how well rocky is walking today 
and to watch videos of other dogs 
who have benefited from the vCiC 
pain management research, please go 
to www.vet.upenn.edu/bellwether.
